secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001157523-23-000343
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q4 2022 net loss $19.4M; cash $352M; advancing EDG-5506 and EDG-7500 trials
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $352M as of Dec 31, 2022.
- Q4 2022 net loss $19.4M ($0.31 per share); R&D expenses $16.6M, G&A $5.5M.
- EDG-7500 for HCM entered IND-enabling studies; Phase 1 start expected 2H2023.
- LYNX Phase 2 DMD trial interim data expected Q4 2023; ARCH BMD 12-month data Q2 2023.
- CANYON BMD trial to be amended with potentially registration-enabling cohort in 2H2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/0001157523-23-000343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/a53339740.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer